Macrophages in spinal cord injury: Phenotypic and functional change from exposure to myelin debris

GLIA

Volumn 63, Issue 4, 2015, Pages 635-651

  Wang, Xi ^a,b   Cao, Kai ^a,c   Sun, Xin ^a   Chen, Yongxiong ^a   Duan, Zhaoxia ^a   Sun, Li ^d   Guo, Lei ^d   Bai, Paul ^a   Sun, Dongming ^a   Fan, Jianqing ^e   He, Xijing ^b   Young, Wise ^a   Ren, Yi ^d  

^a RUTGERS UNIVERSITY   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^d FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e PRINCETON UNIVERSITY   (United States)

Author keywords

Foamy cells; Macrophages; Myelin debris; Spinal cord injury

Indexed keywords

ABC TRANSPORTER A1; CHEMOKINE RECEPTOR CX3CR1; CHOLESTEROL; GALAPTIN; LIPID; MAC 2 PROTEIN; MYELIN; UNCLASSIFIED DRUG; ABCA1 PROTEIN, MOUSE; BIOLOGICAL MARKER; CD11B ANTIGEN; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, MOUSE; GALECTIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL INFILTRATION; CELL PHAGOCYTOSIS; CELLULAR DISTRIBUTION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; FOAM CELL; HOMEOSTASIS; IN VITRO STUDY; INFLAMMATION; LIPID STORAGE; M1 MACROPHAGE; M2 MACROPHAGE; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; MICROGLIA; MOUSE; NEUROPATHOLOGY; NEUROTOXICITY; NEUTROPHIL; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD INJURY; SPINAL CORD LESION; TISSUE INJURY; WOUND HEALING IMPAIRMENT; ANIMAL; CYTOLOGY; DISEASE MODEL; IMMUNOLOGY; METABOLISM; MYELIN SHEATH; PHAGOCYTOSIS; SIGNAL TRANSDUCTION;

ANIMALS; ATP BINDING CASSETTE TRANSPORTER 1; BIOMARKERS; DISEASE MODELS, ANIMAL; GALECTIN 3; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGE-1 ANTIGEN; MACROPHAGES; MICE; MICROGLIA; MYELIN SHEATH; PHAGOCYTOSIS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES;

EID: 84922768570     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22774     Document Type: Article

References (72)

1. Almad A, Sahinkaya FR, McTigue DM. 2011. Oligodendrocyte fate after spinal cord injury. Neurotherapeutics 8:262-873.
2. Beck KD, Nguyen HX, Galvan MD, Salazar DL, Woodruff TM, Anderson AJ. 2010. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: Evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 133(Pt 2):433-447.
3. Bensinger SJ, Tontonoz P. 2008. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:470-477.
4. Bogie JFJ, Timmermans S, Van Anh H-T, Irrthum A, Smeets HJM, Gustafsson J-A, Steffensen KR, Mulder M, Stinissen P, Hellings N, Hendriks JJ. 2012. Myelin-derived lipids modulate macrophage activity by liver X receptor activation. Plos One 7.
5. Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, Aerts JM, Amor S, Nieuwenhuis EE, Laman JD. 2006. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129(Pt 2):517-526.
6. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA, Christ F, Schwab ME. 2000. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 403:434-439.
7. Chinetti G, Fruchart JC, Staels B. 2003. Peroxisome proliferator-activated receptors: New targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipid 14:459-468.
8. Chiu IM, Phatnani H, Kuligowski M, Tapia JC, Carrasco MA, Zhang M, Maniatis T, Carroll MC. 2009. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci U S A 106:20960-20965.
9. Condeelis J, Pollard JW. 2006. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263-266.
10. David S, Kroner A. 2011. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci 12:388-399.
11. Geissmann F, Jung S, Littman DR. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19:71-82.
12. Glim JE, Vereyken EJF, Heijnen DAM, Vallejo JJG, Dijkstra CD. 2010. The Release of Cytokines by Macrophages Is Not Affected by Myelin Ingestion. Glia 58:1928-1936.
13. Gordon S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3:23-35.
14. Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5:953-964.
15. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
16. Hines DJ, Hines RM, Mulligan SJ, Macvicar BA. 2009. Microglia processes block the spread of damage in the brain and require functional chloride channels. Glia 57:1610-1618.
17. Hong C, Tontonoz P. 2008. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 18:461-467.
18. Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, Tang J. 2008. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 1215:218-224.
19. Imai M, Watanabe M, Suyama K, Osada T, Sakai D, Kawada H, Matsumae M, Mochida J. 2008. Delayed accumulation of activated macrophages and inhibition of remyelination after spinal cord injury in an adult rodent model. J Neurosurg Spine 8:58-66.
20. Istvan ES, Deisenhofer J. 2001. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164.
21. Ito D, Tanaka K, Suzuki S, Dembo T, Fukuuchi Y. 2001. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 32:1208-1215.
22. Jeon SB, Yoon HJ, Park SH, Kim IH, Park EJ. 2008. Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brain-resident immune cells. J Immunol 181:8077-8087.
23. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR. 2000. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20:4106-4114.
24. Jurevics H, Morell P. 1995. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 64:895-901.
25. Kasama T, Miwa Y, Isozaki T, Odai T, Adachi M, Kunkel SL. 2005. Neutrophil-derived cytokines: Potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 4:273-279.
26. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. 2009. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29:13435-13444.
27. Kigerl KA, McGaughy VM, Popovich PG. 2006. Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury. J Comp Neurol 494:578-594.
28. Kim YS, Joh TH. 2006. Microglia, major player in the brain inflammation: Their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38:333-347.
29. Kroner A, Greenhalgh AD, Zarruk JG, Passos Dos Santos R, Gaestel M, David S. 2014. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron 83:1098-1116.
30. Kwon BK, Okon E, Hillyer J, Mann C, Baptiste D, Weaver LC, Fehlings MG, Tetzlaff W. 2011. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 28:1545-1588.
31. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. 1999. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 104:R25-R31.
32. Loke P, Nair MG, Parkinson J, Guiliano D, Blaxter M, Allen JE. 2002. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol 3:7.
33. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677-686.
34. McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE. 1994. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 13:805-811.
35. McTigue DM, Tripathi R, Wei P, Lash AT. 2007. The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol 205:396-406.
36. Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, Cardona AE. 2012. The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol 188:29-36.
37. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958-969.
38. Nguyen HX, Beck KD, Anderson AJ. 2011. Quantitative assessment of immune cells in the injured spinal cord tissue by flow cytometry: A novel use for a cell purification method. J Vis Exp 50:2698.
39. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A. 2007. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116-1120.
40. Oram JF, Heinecke JW. 2005. ATP-binding cassette transporter A1: A cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85:1343-1372.
41. Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R. 2007. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 320:1002-1012.
42. Pereira MP, Hurtado O, Cardenas A, Bosca L, Castillo J, Davalos A, Vivancos J, Serena J, Lorenzo P, Lizasoain I, Moro MA. 2006. Rosiglitazone and 15-deoxy-Delta12, 14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 26:218-229.
43. Pineau I, Lacroix S. 2007. Proinflammatory cytokine synthesis in the injured mouse spinal cord: Multiphasic expression pattern and identification of the cell types involved. J Comp Neurol 500:267-285.
44. Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, Gomez-Aguado F, Ratnam M, Sanchez-Mateos P, Corbi AL. 2009. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 69:9395-9403.
45. Rauh MJ, Ho V, Pereira C, Sham A, Sly LM, Lam V, Huxham L, Minchinton AI, Mui A, Krystal G. 2005. SHIP represses the generation of alternatively activated macrophages. Immunity 23:361-374.
46. Ren Y, Savill J. 1998. Apoptosis: The importance of being eaten. Cell Death Differ 5:563-568.
47. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. 2003. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48:2888-2897.
48. Ren Y, Xie Y, Jiang G, Fan J, Yeung J, Li W, Tam PK, Savill J. 2008. Apoptotic cells protect mice against lipopolysaccharide-induced shock. J Immunol 180:4978-4985.
49. Ren Y, Young W. 2013. Managing inflammation after spinal cord injury through manipulation of macrophage function. Neural Plast 2013:945034.
50. Roney KE, O'Connor BP, Wen H, Holl EK, Guthrie EH, Davis BK, Jones SW, Jha S, Sharek L, Garcia-Mata R, Bear JE, Ting JP. 2011. Plexin-B2 negatively regulates macrophage motility, Rac, and Cdc42 activation. PLoS One 6:e24795.
51. Rotshenker S. 2003. Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease. J Mol Neurosci 21:65-72.
52. Rotshenker S, Reichert F, Gitik M, Haklai R, Elad-Sfadia G, Kloog Y. 2008. Galectin-3/MAC-2, Ras and PI3K activate complement receptor-3 and scavenger receptor-AI/II mediated myelin phagocytosis in microglia. Glia 56:1607-1613.
53. Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, Ransohoff RM, Charo IF. 2010. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 5:e13693.
54. Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA. 2005. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8:468-475.
55. Savill J, Dransfield I, Gregory C, Haslett C. 2002. A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2:965-975.
56. Shechter R, London A, Varol C, Raposo C, Cusimano M, Yovel G, Rolls A, Mack M, Pluchino S, Martino G, Jung S, Schwartz M. 2009. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 6:e1000113.
57. Sica A, Bronte V. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117:1155-1166.
58. Sica A, Schioppa T, Mantovani A, Allavena P. 2006. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 42:717-727.
59. Sierra-Filardi E, Vega MA, Sanchez-Mateos P, Corbi AL, Puig-Kroger A. 2010. Heme oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiology 215:788-795.
60. Smith ME. 1999. Phagocytosis of myelin in demyelinative disease: A review. Neurochem Res 24:261-268.
61. Sun X, Wang X, Chen T, Li T, Cao K, Lu A, Chen Y, Sun D, Luo J, Fan J, Young W, Ren Y. 2010. Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-dependent inflammatory response in murine system. PLoS One 5:e9380.
62. Totoiu MO, Keirstead HS. 2005. Spinal cord injury is accompanied by chronic progressive demyelination. J Comp Neurol 486:373-383.
63. Van Rossum D, Hilbert S, Strassenburg S, Hanisch U-K, Brueck W. 2008. Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype. Glia 56:271-283.
64. VanderLaan LJW, Ruuls SR, Weber KS, Lodder IJ, Dopp EA, Dijkstra CD. 1996. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: Phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. Journal of Neuroimmunology 70:145-152.
65. Vargas ME, Barres BA. 2007. Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci 30:153-179.
66. Wang X, Chen T, Leng L, Fan J, Cao K, Duan Z, Zhang X, Shao C, Wu M, Tadmori I, Li T, Liang L, Sun D, Zheng S, Meinhardt A, Young W, Bucala R, Ren Y. 2012. MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation. Cancer Res 72:2867-2878.
67. Wolfs IM, Donners MM, de Winther MP. 2011. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost 106:763-771.
68. Xiao L, Hu C, Yang W, Guo D, Li C, Shen W, Liu X, Aijun H, Dan W, He C. 2013. NMDA receptor couples Rac1-GEF Tiam1 to direct oligodendrocyte precursor cell migration. Glia 61:2078-2099.
69. Yang RY, Rabinovich GA, Liu FT. 2008. Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med 10:e17.
70. Young W. 2002. Spinal cord contusion models. Prog Brain Res 137:231-255.
71. Yvan-Charvet L, Wang N, Tall AR. 2010. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 30:139-143.
72. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J. 2006. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20:1162-1175.